Alveus raises $159.8 million to develop weight‑loss maintenance therapies.

Alveus Therapeutics secured $159.8 million in a Series A round to advance treatments aimed at sustaining weight loss, including ALV‑100 and ALV‑200, the article reports.

Alveus Therapeutics said it raised $159.8 million in a Series A financing to support development of treatments designed to help people keep weight off over the long term. The company highlighted that many current obesity medicines are stopped within a year or two and that weight is often regained after treatment ends. Alveus is developing ALV‑100, reported as a compound combining GLP‑1 activation with GIP receptor blocking, and ALV‑200, an amylin‑based therapy that has entered the regulatory filing stage. The funding round was led by New Rhein Healthcare Investors, Andera Partners and Omega Funds, with participation from Sanofi Capital and others. Key points: - The company raised $159.8 million in Series A financing led by New Rhein Healthcare Investors, Andera Partners and Omega Funds, with participation from Sanofi Capital. - ALV‑100 is described in the article as combining GLP‑1 activation — the mechanism behind drugs such as Wegovy — with blocking of GIP receptors, aimed at more durable weight loss. - ALV‑200 is an amylin‑based therapy reported to have entered the regulatory filing stage and is designed to preserve lean muscle during weight loss. - The article reports that about half of patients stop current obesity medications within a year and 85% discontinue by year two, and that weight often returns after stopping therapy. Summary: The funding is intended to advance Alveus’s focus on weight‑loss maintenance and tolerability rather than solely on initial pounds lost. Undetermined at this time.